Dr. Jingyan Tang

Dr. Jingyan Tang is a distinguished pediatric hematologist and oncologist based at the Shanghai Children’s Medical Center in China. She holds the position of Chief Physician in the Department of Hematology and Oncology and is also a doctoral supervisor. Dr. Tang serves as the Director of the National Key Laboratory of Pediatric Hematology and Oncology under the National Health Commission.

Professional Background
• Clinical Title: Chief Physician
• Practice Location: Shanghai Children’s Medical Center, Professional Experience

Dr. Tang has extensive international experience, having completed fellowships at several renowned institutions:

• 1994: Fellowship at Columbus Children’s Hospital, USA (1 year)
• 1994: Fellowship at St. Jude Children’s Research Hospital, USA (3 months)
• 2001: Fellowship at MD Anderson Cancer Center, USA (1 year)

Research Focus

Dr. Tang specializes in the diagnosis and treatment of various pediatric solid tumors and hematological/oncological conditions, including:
• Neuroblastoma
• Wilms’ tumor (renal cell carcinoma)
• Extragonadal germ cell tumors
• Hepatoblastoma
• Lymphoma
• Pediatric hematological and oncological disorders such as Langerhans cell histiocytosis

Expertise and Clinical Practice

She is recognized for her expertise in managing complex pediatric cancer cases and providing comprehensive care for children with hematological and oncological conditions.

Dr. Tang’s international training and leadership in research make her a leading figure in pediatric hematology and oncology in China.

Dr. Jingyan Tang is a distinguished pediatric hematologist and oncologist who has significantly advanced the field of pediatric cancer research and treatment in China. She earned her medical degree from Shanghai Jiao Tong University School of Medicine in 1982.

Throughout her illustrious career spanning over four decades, Dr. Tang held several prominent positions, including:

• Chairperson of the Hematology/Oncology Department at Shanghai Children’s Medical Center (SCMC).
• Chairperson of the Chinese Children’s Cancer Group.
• Chairperson of the Chinese Pediatric Cancer Key Laboratory under the National Health Commission.

At SCMC, Dr. Tang played a pivotal role in developing effective and affordable treatment protocols for pediatric acute lymphoblastic leukemia (ALL), significantly improving remission rates among underprivileged children. Her collaborative research with international institutions led to the establishment of the Chinese Children’s Tumor (Leukemia) Clinical Multi-center Research Group, enhancing the accessibility of advanced treatments across China.

Dr. Tang’s research interests focused on medical genetics, molecular diagnostics, and embryo engineering. She has authored over 200 publications, contributing extensively to the understanding and treatment of pediatric hematological malignancies.

In recognition of her outstanding contributions, Dr. Tang was awarded the Second Prize by the Chinese Medical Association in 2018. She retired in 2022, leaving behind a legacy of excellence in pediatric hematology and oncology.

Dr. Jingyan Tang is a distinguished pediatric hematologist and oncologist who has significantly advanced the field of pediatric cancer research and treatment in China. She earned her medical degree from Shanghai Jiao Tong University School of Medicine in 1982.

Throughout her illustrious career spanning over four decades, Dr. Tang held several prominent positions, including:

• Chairperson of the Hematology/Oncology Department at Shanghai Children’s Medical Center (SCMC).
• Chairperson of the Chinese Children’s Cancer Group.
• Chairperson of the Chinese Pediatric Cancer Key Laboratory under the National Health Commission.

At SCMC, Dr. Tang played a pivotal role in developing effective and affordable treatment protocols for pediatric acute lymphoblastic leukemia (ALL), significantly improving remission rates among underprivileged children. Her collaborative research with international institutions led to the establishment of the Chinese Children’s Tumor (Leukemia) Clinical Multi-center Research Group, enhancing the accessibility of advanced treatments across China.

Dr. Tang’s research interests focused on medical genetics, molecular diagnostics, and embryo engineering. She has authored over 200 publications, contributing extensively to the understanding and treatment of pediatric hematological malignancies.

In recognition of her outstanding contributions, Dr. Tang was awarded the Second Prize by the Chinese Medical Association in 2018. She retired in 2022, leaving behind a legacy of excellence in pediatric hematology and oncology.

Dr. Jingyan Tang is a distinguished pediatric hematologist and oncologist who has dedicated over four decades to the diagnosis and treatment of various pediatric hematological and oncological conditions. Based at the Shanghai Children’s Medical Center, her expertise encompasses a broad spectrum of pediatric blood disorders and cancers.

Diseases Treated by Dr. Jingyan Tang

Dr. Tang has extensive experience in managing the following conditions:

• Acute Lymphoblastic Leukemia (ALL): A common type of leukemia in children, characterized by the rapid growth of abnormal white blood cells.
• Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow that affects the production of normal blood cells.
• Chronic Myeloid Leukemia (CML): A type of cancer that starts in certain blood-forming cells of the bone marrow and invades the bloodstream.
• Lymphomas: Cancers of the lymphatic system, including Hodgkin and non-Hodgkin lymphomas.
• Bone Marrow Failure Syndromes: Disorders where the bone marrow does not produce sufficient blood cells, leading to anemia, infections, or bleeding.
• Solid Tumors: Various types of cancerous growths that form in solid tissues, such as neuroblastoma, Wilms tumor, and rhabdomyosarcoma.

Her research has also contributed to understanding the psychosocial outcomes in pediatric cancer survivors, highlighting the importance of long-term follow-up care.

Dr. Tang’s work has been instrumental in improving treatment protocols and outcomes for children with these conditions, particularly in the context of China’s healthcare landscape.

Medical Treatments:

• Chemotherapy: Utilizing pharmaceutical agents to target and eliminate cancer cells.​

• Radiation Therapy: Employing high-energy radiation to shrink tumors and eradicate malignant cells.​

• Stem Cell Transplantation: Transferring healthy stem cells to restore bone marrow function in patients with hematological malignancies.​

• CAR T-Cell therapy: A pioneer in CAR-T therapy, Dr. Tang specializes in developing and administering personalized CAR-T treatments for B-cell malignancies, including B-ALL and certain lymphomas.